Is the price fair?
What ICLR's price assumes
ICON Public Limited Company trades at 74.0× earnings against 33.6× for the median Diagnostics & Research name, more expensive than its own group.
74.0
Trailing P/E · Diagnostics & Research median 33.6 · 2.20× the median: the market pays up for this one
- Price / sales
- 1.03
Price / sales · as of 2026-Q1
- Free cash flow yield
- 6.2%
Free cash flow yield · Diagnostics & Research median 4.2%
- Growth the price implies
- +2.9%
Growth the price implies · The price pays for +2.9% free cash flow growth a year for a decade; the business has delivered +28% a year over the last three.
Details›
- Price / book2026-Q1
- 0.92
- EV / EBIT2026-Q1
- 27.3
- EV / sales2026-Q1
- 1.29
- Healthcare median P/E362 names
- 29.9
- Diagnostics & Research median P/E29 names
- 33.6
- Free cash flow, trailing twelve months
- $759M
- Market capitalisation
- $12.3B
- 3-year revenue growth
- +1.9%
- 3-year free cash flow growth
- +28%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $50.53 |
| Its own P/E history, median | $65.62 |
| Its own P/E history, upper quartile | $91.18 |
| 52-week range | $80.08 – $202.92 |
| Today | $158.47 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #17 of 17 by Smart Score